Glialogix Inc., of San Francisco, said it entered a sponsored research agreement with Fast Forward, a nonprofit organization established by the National Multiple Sclerosis Society, which will provide funding to the company for preclinical studies of GLX1112, a neuroprotective therapy designed to slow the accumulation of disability in progressive multiple sclerosis.